Title
In vitro time-kill curves study of three antituberculous combinations against Mycobacterium tuberculosis clinical isolates
Date Issued
01 January 2016
Access level
metadata only access
Resource Type
journal article
Author(s)
López-Gavín A.
Tudó G.
Rey-Jurado E.
Vergara A.
Gonzalez-Martín J.
Universidad de Barcelona
Publisher(s)
Elsevier B.V.
Abstract
The objective of this study was to examine the in vitro synergism of three-drug combinations against Mycobacterium tuberculosis (levofloxacin/linezolid/ethambutol, levofloxacin/amikacin/ethambutol and levofloxacin/linezolid/amikacin) using the time-kill curves method. In total, 8 multidrug-resistant and 12 drug-susceptible M. tuberculosis isolates were used. Minimum inhibitory concentrations (MICs) of the isolates for each drug were determined by the proportions method. Time-kill curves were studied for the three combinations proposed over 14 days using two different protocols. In protocol 1, 0.5× MIC for each drug was used. In protocol 2, 0.5× MIC for levofloxacin and linezolid and 0.25× MIC for amikacin and ethambutol were used. The MICs for all of the isolates studied were 0.5 mg/L for levofloxacin and linezolid and 2.5 mg/L for ethambutol and amikacin. All of the combinations displayed an additive activity compared with the most active individual drug. In conclusion, these results demonstrate that the three combinations tested were equally effective against M. tuberculosis isolates. The study of antituberculous combinations using in vitro methods is an excellent first step to predict their effect in clinical development phases as well as to test new regimens of the antituberculous drugs currently available.
Start page
97
End page
100
Volume
47
Issue
1
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Scopus EID
2-s2.0-84953839279
PubMed ID
Source
International Journal of Antimicrobial Agents
ISSN of the container
09248579
Sponsor(s)
This study was supported by the Ministerio de Economía y Competitividad , Instituto de Salud Carlos III , co-financed by the European Regional Development Fund (ERDF, FEDER) ‘A Way to Achieve Europe’, the Spanish Ministry of Health [grant nos. FIS10/0712 and FIS13/01752 ], the Spanish Network for Research in Infectious Diseases [ REIPI RD12/0015 to GT] and the Sociedad Española de Neumología y Cirugía Torácica [ SEPAR 1007/2010 ]. This study was also supported by grant 2014 SGR 653 from the Departament d’Universitats, Recerca i Societat de la Informació, of the Generalitat de Catalunya.
Sources of information: Directorio de Producción Científica Scopus